What Is CBD Oil – Benefits, Uses & Legality in Europe

Updated June 2026 · Last reviewed for accuracy and compliance.

CBD oil is one of the most-searched cannabis-derived products in Europe — and one of the most misunderstood. This pillar guide explains what CBD oil actually is, where it comes from, how cannabidiol interacts with the human body, what published research has examined, the European legal landscape country by country, how to choose strength and format, how to dose responsibly, the safety profile and drug interactions, who should avoid it, and the quality markers that separate compliant European products from the unregulated long tail. It is educational and is not personal medical advice.

If you arrived here from a search like “what is CBD oil”, “CBD oil benefits”, “is CBD oil legal in Europe”, “how does CBD work”, “CBD oil dosage”, “CBD oil side effects” or “CBD vs THC”, this guide answers each of those questions in turn. Use the sub-headings to navigate to the section you need.

What CBD oil actually is

CBD oil is a liquid food-supplement format in which cannabidiol (CBD) — one of more than 100 cannabinoids identified in Cannabis sativa L. (hemp) — is suspended in a carrier oil. The carrier is typically medium-chain triglyceride (MCT) oil, cold-pressed hemp seed oil, or olive oil. The CBD itself is extracted from industrial hemp using one of three principal methods: supercritical CO₂ extraction (the pharmaceutical-grade standard), food-grade ethanol extraction, or hydrocarbon extraction (which we do not use).

A bottle of CBD oil is labelled in two ways that matter: the total milligrams of cannabidiol in the bottle (for example 1,000 mg in 10 ml) and the percentage strength (10% in that example). Dividing total mg by bottle size gives mg-per-ml. Dividing mg-per-ml by 20 (the standard drop count for a 1 ml dropper) gives mg-per-drop. Knowing these three numbers lets you reason about dose. Our CBD Oil Strength Guide walks through this maths in full.

CBD is non-intoxicating. It does not produce the psychoactive effects associated with THC (delta-9-tetrahydrocannabinol). This is the single most consistent finding across the entire CBD research literature and the WHO’s 2018 critical review (WHO CBD Critical Review), which also found no evidence of abuse or dependence potential at the doses studied. Non-intoxicating does not mean inert: CBD has measurable pharmacology and interacts with prescription medications. We cover both points below.

Where CBD comes from — the hemp plant

All CBD sold legally in the EU and UK as a food supplement is derived from industrial hemp — cultivars of Cannabis sativa L. selectively bred for low THC content. European industrial hemp must by definition contain less than 0.3% THC at the cultivation stage (raised from the previous 0.2% threshold under the 2023 EU Common Agricultural Policy update). The finished food supplement is held to even tighter limits in most member states.

Hemp is grown across the EU at meaningful scale — France is the largest producer, followed by the Netherlands, Italy, Romania, Lithuania and Germany. Industrial hemp serves three distinct markets simultaneously: fibre (for textiles, building materials, paper), seed and oil (for food and cosmetics), and cannabinoid extraction (CBD, CBG, CBN and emerging minor cannabinoids). See Ukraine industrial hemp facility and hemp history Ukraine and Russia for the broader European sector context.

How CBD works — the endocannabinoid system

The reason CBD has measurable effects in mammals at all is that humans have an endogenous signalling system — the endocannabinoid system (ECS) — that interacts with cannabinoids. The ECS was characterised in the late 20th century by Raphael Mechoulam and colleagues and has three principal components: cannabinoid receptors (CB1 and CB2), endogenous ligands (anandamide and 2-arachidonoylglycerol, abbreviated 2-AG) and the metabolic enzymes that build and break them down (FAAH and MAGL).

How CBD differs from THC at the receptor level

THC binds directly to the CB1 receptor as an agonist. That direct activation in central nervous system CB1 receptors is what produces THC’s intoxicating effect. CBD does not bind strongly to CB1 in the same agonist way; instead it acts primarily through indirect modulation of the endocannabinoid system, plus action at a number of non-cannabinoid receptors including the serotonin 5-HT1A receptor, the vanilloid TRPV1 receptor, and PPAR receptors (de Almeida 2020 mechanism review). This different mechanism is why CBD does not produce intoxication despite acting on receptors involved in mood, pain perception and inflammation.

CBD and the “entourage effect”

Full-spectrum CBD oil contains not just cannabidiol but the minor cannabinoids (CBC, CBG, CBN, traces of THC under the legal threshold) and the terpenes that survive extraction. The hypothesis — first articulated by Ben-Shabat and Mechoulam in 1998 and elaborated by Ethan Russo in 2011 — is that these minor compounds interact synergistically with CBD, producing effects that pure isolate does not (Ben-Shabat 1998, Russo 2011). The entourage hypothesis is mechanistically plausible and widely cited. Robust clinical evidence isolating the effect remains limited. See Full Spectrum vs Broad Spectrum vs Isolate for a complete breakdown of formats.

What published research has examined

We separate the CBD research landscape into two categories because the regulatory implications are completely different.

Pharmaceutical CBD — where clinical evidence is established

Cannabidiol is an approved pharmaceutical medicine in the form of Epidiolex (UK / EU) and Epidyolex, indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in patients aged two and over. The approval followed two landmark double-blind randomised controlled trials by Devinsky and colleagues for Dravet syndrome (Devinsky 2017) and Lennox-Gastaut syndrome (Thiele 2018). The doses used in those trials (typically 10-20 mg/kg/day) are pharmaceutical doses, considerably higher than typical food-supplement intake, and are administered under medical supervision with hepatic monitoring.

Food-supplement CBD — where research is preliminary

For every other context — sleep, anxiety, pain, mood, inflammation, dermatology — the food-supplement CBD evidence is preliminary. The WHO 2018 critical review found CBD generally well tolerated with a good safety profile at the doses studied. Iffland and Grotenhermen’s 2017 safety review (Iffland 2017) reached the same conclusion. But “well tolerated” is not “clinically effective for condition X”. Specific outcome research — Shannon 2019 on anxiety and sleep (Shannon 2019), Bergamaschi 2011 on social anxiety disorder (Bergamaschi 2011), Suraev 2022 systematic review on sleep (Suraev 2022) — describes small studies, mixed results, and the need for larger trials. Our individual cluster articles (sleep, stress, pain, focus) walk through what each line of research has and has not established.

Is CBD oil legal in Europe? — country-by-country

CBD is broadly legal across the EU and UK as a food supplement, but the regulatory detail matters and varies by country. Two layers apply: the EU Novel Food Regulation (which classifies most CBD extracts as novel foods requiring authorisation) and national-level positions on sale, advertising and shipping.

United Kingdom

CBD food supplements are legal under the Novel Food framework administered by the FSA, provided products are on the FSA validated list and contain no detectable THC above the 1 mg-per-container limit. UK consumers can purchase compliant CBD food supplements freely.

Netherlands

The Dutch coffeeshop framework — for cannabis flower and hashish — operates separately from the food-supplement category. Hemp-derived CBD is sold legally in specialist stores, pharmacies and online. See where to buy CBD oil in the Netherlands.

Germany

CBD food supplements have an evolving regulatory position. The 2024 cannabis reform legalised limited personal cannabis use under a distinct framework but did not change novel-food rules for CBD. German customs has historically scrutinised cross-border CBD shipments. Recent German hemp tax stamps regulation represents a formalisation step.

France, Italy, Spain

All three permit hemp-derived CBD food supplements under EU novel-food rules. France updated its position in 2022 following the European Court of Justice’s Kanavape decision, which struck down France’s ban on CBD imported from other EU member states. Italy has its own CBD regulatory history. Spain’s position is similar.

Other EU markets

Belgium, Portugal, Ireland, Sweden, Denmark, Austria, the Czech Republic, Poland and most other EU states permit hemp-derived CBD food supplements. Malta’s 2026 amendments are clarifying its position.

Greece — important THCP note

Greece classified THCP as a controlled substance in 2025. THCP is a distinct cannabinoid from CBD; CBD food supplements remain legal in Greece. THC gummies in Greece covers the practical implications.

CBD oil benefits — what reasonable users seek it for

We make no health claims for our food supplements, and we frame everything in research terms. Within those limits, here is what research has examined and what users describe.

Sleep and relaxation

Detailed in CBD oil for sleep. Many users take an evening dose alongside sleep-hygiene fundamentals. Some prefer CBN-leaning formulations — see CBN vs CBD for sleep.

Stress and everyday anxiety

Detailed in CBD oil for stress & anxiety. Distinct from diagnosed anxiety disorders, which require clinical care. NHS Every Mind Matters (nhs.uk/every-mind-matters) is the right evidence-based first step.

Discomfort and inflammation

Detailed in CBD oil for pain. The pharmaceutical cannabinoid medicine for spasticity is nabiximols (Sativex), which is a different product category from food-supplement CBD.

Daytime wellbeing and focus

Detailed in CBD oil for focus. Some users prefer CBG-leaning daytime formulations — see CBG vs CBD daytime guide.

CBD oil dosage — how to think about dose

There is no one-size-fits-all CBD dose because absorption, metabolism, body composition, the carrier oil and the cannabinoid spectrum all vary. The published research and the FSA’s general guidance converge on a sensible practical framework.

Start low, increase slowly

A reasonable starting point for a first-time user is 5-10 mg cannabidiol once daily, taken sublingually (under the tongue, held for 30-60 seconds before swallowing). Maintain that dose for one to two weeks before adjusting. If you do not notice the effect you are looking for, increase by 5-10 mg per step and hold each new step for at least a week. Most regular food-supplement users settle between 15 mg and 50 mg per day.

The FSA’s 10 mg per day reference

The UK Food Standards Agency’s 2023 review of CBD intake recommended a provisional acceptable daily intake of 10 mg per day, based on a precautionary read of liver enzyme data from the high-dose Epidiolex trials. This is a regulatory precautionary number, not a clinical efficacy threshold; many compliant food-supplement users take more. Talk to your pharmacist if you exceed it.

Timing — morning, evening, or both?

CBD does not have a single “correct” time. Many users split a daily dose: a morning dose for general daytime wellbeing and an evening dose as part of a wind-down routine. Take with a meal containing some fat — bioavailability is higher with food (Birnbaum 2019).

Sublingual vs swallowed vs gummy

Sublingual application allows partial absorption through the oral mucosa, with the remainder swallowed and subject to first-pass hepatic metabolism. Onset is typically 15-45 minutes for sublingual, 45-90 minutes for swallowed or gummy. Sublingual gives faster onset; gummies give convenience and consistent dose per piece.

CBD oil side effects and safety

Full detail in CBD oil side effects and safety. The short summary: drowsiness, dry mouth, mild gastrointestinal effects, occasional appetite change, and (at high pharmaceutical doses) liver enzyme elevations. The most important safety consideration in food-supplement use is not direct toxicity but drug interactions.

Drug interactions — the CYP450 story

CBD inhibits several cytochrome P450 enzymes, principally CYP3A4 and CYP2C19. Many prescription medications are metabolised by those enzymes; CBD can therefore alter their plasma concentrations. Categories of medication where the interaction matters include certain anti-epileptics (notably clobazam, valproate, brivaracetam), anticoagulants (warfarin), several antidepressants (some SSRIs and SNRIs), beta blockers, some statins, certain immunosuppressants, certain anti-virals and PrEP medication, certain chemotherapy and hormone-therapy agents, and benzodiazepines (CBD drug interactions review).

The practical rule is simple: if you take a prescription medication, tell your pharmacist or prescriber that you are considering or already taking CBD. Do not stop or reduce a prescription medication because you are taking CBD.

Who should not use CBD oil

Pregnancy and breastfeeding — insufficient safety data. Under-18s — food-supplement CBD is not appropriate for paediatric use (pharmaceutical CBD for paediatric epilepsy is a different product). People with significant hepatic impairment — discuss with a clinician first. People taking medications with narrow therapeutic windows in the categories above — prescriber sign-off required.

Choosing a quality CBD oil — what to actually look for

The CBD market is uneven on quality. The marker that matters most is a per-batch Certificate of Analysis (COA) from an independent laboratory, covering cannabinoid content (does the bottle contain what the label says?), residual solvents (no benzene, hexane, toluene), heavy metals (lead, cadmium, mercury, arsenic) and microbial screening (no yeast, mould, E. coli). A reputable European supplier will publish COAs by batch number on the product page.

Independent certification — CAN

The Cannabinoid Association Netherlands runs an independent certification programme that audits production, sourcing and labelling against a published standard. Our award-winning No.15 range and 50% Pure Isolate carry the CAN seal. See what CAN certification means.

Extraction and carrier oils

Look for CO₂ or food-grade ethanol extraction; avoid hydrocarbon-extracted products. Cold-pressed hemp seed oil or organic-certified MCT are the best carrier choices. SKAL bio-organic certification (the Dutch organic mark) provides another quality signal.

Industry recognition

Our CBG-CBD No.15, CBN-CBD No.15 and CBD Madness Oil No.30 are Jack Herer Cup winners. Industry recognition is a quality signal — not a regulatory approval and not a therapeutic claim.

Choosing strength and format

Strength is shorthand for cannabinoid concentration: 5% (typically 500 mg / 10 ml) suits first-time users; 10% (1,000 mg / 10 ml) is the most common everyday strength; 15-20% (1,500-2,000 mg / 10 ml) suits experienced users with established routines; 30-50% (3,000-5,000 mg / 10 ml) is reserved for users who have built up tolerance and want a portable high-strength format. See CBD Oil Strength Guide for the full breakdown including dose-per-drop maths.

Format is a separate choice. Sublingual oil is the standard. Gummies, capsules, topicals and (in some markets) cosmetic preparations cover the rest. See CBD cosmetics for cosmetic-grade formulations under EU Cosmetics Regulation 1223/2009.

CBD oil compared to other cannabinoids

CBD is one of more than 100 cannabinoids. The ones most relevant to a food-supplement buyer are CBG (cannabigerol — daytime-leaning, the “mother cannabinoid”) and CBN (cannabinol — nighttime-leaning, the first cannabinoid isolated). For the side-by-side details, see CBG vs CBD and CBN vs CBD. THCV (tetrahydrocannabivarin) and THCP (tetrahydrocannabiphorol) are minor cannabinoids; THCP shipping is restricted to UK and Portugal only from our catalogue. HHC and HHCP — semi-synthetic cannabinoids — are restricted across the EU and UK since 2023-2024 and we have exited those categories entirely.

Frequently asked questions about CBD oil

Where to read next

Practical next steps from this pillar: How to Take CBD Oil (the practical dosing guide) · CBD Oil Strength Guide (choosing concentration) · Full Spectrum vs Broad Spectrum vs Isolate (format choice) · CBD Oil Side Effects (safety and interactions) · CAN Certification (quality framework) · Why Choose Canna Health Amsterdam (our editorial and regulatory posture).

All products sold by Canna Health Amsterdam are food supplements or cosmetics. They are not medicines and are not a substitute for medical care. Statements describe research, not clinical effect. Always consult a qualified healthcare professional before making any change to a treatment plan, especially during pregnancy, breastfeeding or while taking prescription medications. Information current to June 2026.